BioVaxys Technology Corp. (BioVaxys) announced that it has broadened the patent coverage on CoviDTH, its T cell diagnostic for detecting an immune response to SARS-CoV-2,  by filing an international patent application through the Patent Cooperation Treaty (PCT) for broad geographic market coverage outside the US. Although CoviDTH diagnostic results are intended to be visually interpreted by a trained technician or healthcare provider, additional patent claims include data capture and analysis via methods such as optical, infrared, and ultrasonic image processing.

The International Patent Cooperation Treaty (PCT) Application, which is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.   

BioVaxys recently also filed international applications for registration of the CoviDTH trademark in selected markets including Canada, Mexico, European Union and United Kingdom.  Six months ago, the Company filed its application with the United States Patent and Trademark Office (USPTO) for US registration of its "CoviDTH" trademark. Trademark applications in certain countries may be treated as if they had been filed on the filing date of the US application, provided the applications are filed within six months of the US filing date. BioVaxys may still apply for trademark registration of CoviDTH in other countries at a later date, but it will be without the benefit of the earlier US filing date.

BioVaxys CEO James Passin states, "Given the urgent importance of commercializing a low-cost diagnostic for T cell immunity to Covid-19 in the context of the global pandemic, we believe that it critical to protect Intellectual Property in key international markets as we continue to advance to towards the submission of an IND in the United States."

For greater certainty, BioVaxys is not making any express or implied claims that it has the ability to treat the SAR-CoV-2 virus at this time.

Based in Vancouver, BioVaxys Technology Corp. is a British Columbia-registered, clinical stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.